Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

ClinicalTrials.gov ID: NCT00115154

Public ClinicalTrials.gov record NCT00115154. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per week for 16 weeks.

Study identification

NCT ID: NCT00115154
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Enrollment: 270 participants

Conditions and interventions

Conditions

Keratosis

Interventions

Aldara (imiquimod) cream, 5% Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2005 (Type not available)
Primary completion: Not listed
Completion: Sep 2006 (Type not available)
Last update posted: Feb 19, 2007

2005 – 2006

United States locations

U.S. sites: 18
U.S. states: 15
U.S. cities: 18

Facility	City	State	ZIP	Site status
Not listed	Tucson	Arizona	85710	—
Not listed	Vista	California	92083	—
Not listed	Atlanta	Georgia	30263	—
Not listed	Newnan	Georgia	30263	—
Not listed	Buffalo Grove	Illinois	60089	—
Not listed	Evansville	Indiana	47713	—
Not listed	Riverside Park	New Jersey	08075	—
Not listed	New York	New York	10025	—
Not listed	Rochester	New York	14623	—
Not listed	Greenville	North Carolina	27834	—
Not listed	Portland	Oregon	97223	—
Not listed	Providence	Rhode Island	02903	—
Not listed	Knoxville	Tennessee	37922	—
Not listed	Dallas	Texas	75246	—
Not listed	Houston	Texas	77030	—
Not listed	Virginia Beach	Virginia	23454	—
Not listed	Wenatchee	Washington	98801	—
Not listed	Milwaukee	Wisconsin	53209	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00115154, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 19, 2007 · Synced Nov 6, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00115154 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →